10-Q: Jocom Holdings Reports Q3 Loss Amid Strategic Shift, Capital Raise

Jocom Holdings Corp. reported a significant net loss for the nine months ended September 30, 2025, driven by increased operational expenses and a strategic focus on acquisitions, despite a capital raise.

Summary

• Reported a net loss of $126,819 for the nine months ended September 30, 2025, a significant decline from a net profit of $37,218 in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, was $0, down from $18,000 in the prior year, indicating a complete cessation of service fee revenue.
• General and administrative expenses surged to $213,914 for the nine months ended September 30, 2025, compared to $80,165 in the same period of 2024.
• Cash and bank balances increased substantially to $22,987 as of September 30, 2025, from $2,481 at December 31, 2024.
• Total assets grew significantly to $371,778 as of September 30, 2025, from $8,272 at December 31, 2024, primarily due to a large advance payment for a planned acquisition.
• Equity turned positive, reaching $306,769 as of September 30, 2025, from a negative $(68,561) at December 31, 2024, largely due to proceeds from common stock issuance.
• The company raised $800,000 through unregistered sales of 8,000,000 common shares at $0.10 per share during the period.
• A $348,000 advance payment was made as earnest money for the planned acquisition of Yijun (Shanghai) Biotecholgy Co Ltd., expected to be completed by Q2 2026.
• The subsidiary JHC Digital Sdn. Bhd. completed its strike-off on August 4, 2025.
• Management identified material weaknesses in internal controls over financial reporting, including a lack of a functioning audit committee, inadequate segregation of duties, insufficient written policies, and absence of an internal audit function.
• The company's ability to continue as a going concern is in substantial doubt due to accumulated losses and negative operating cash flows.

Sentiment

Score: 2

Explanation: The company reported zero revenue, a significant net loss, and substantial negative operating cash flow. It also received a going concern warning and disclosed material weaknesses in internal controls. While a capital raise occurred and an acquisition is planned, the current operational and financial health is severely distressed.

Positives

• Cash and cash equivalents increased significantly to $22,987 as of September 30, 2025, from $2,481 at December 31, 2024.
• Total stockholders' equity turned positive to $306,769 as of September 30, 2025, from a negative $(68,561) at December 31, 2024.
• Successfully raised $800,000 through the issuance of 8,000,000 common shares, providing capital for operations and strategic initiatives.
• Made a substantial advance payment of $348,000 towards the acquisition of Yijun (Shanghai) Biotecholgy Co Ltd., signaling progress on long-term strategic growth.
• Amount due to directors was fully repaid, decreasing from $6,019 to $0.

Negatives

• Reported a net loss of $126,819 for the nine months ended September 30, 2025, a significant deterioration from a net profit of $37,218 in the prior year.
• Revenue dropped to $0 for the nine months ended September 30, 2025, from $18,000 in the same period of 2024, indicating a complete loss of core service revenue.
• General and administrative expenses increased significantly to $213,914 for the nine months ended September 30, 2025, from $80,165 in the prior year.
• Net cash used in operating activities was $(479,644) for the nine months ended September 30, 2025, a substantial negative shift from net cash generated of $10,493 in the prior year.
• Accumulated losses increased to $(775,569) as of September 30, 2025, from $(644,528) at December 31, 2024.
• The intangible asset "AI Smart Platform" was written off, indicating a potential loss of value or change in strategy regarding this asset.
• A new "Subscription receivable" of $(300,000) appeared on the balance sheet, reducing total equity.

Risks

• Going Concern Doubt: The company incurred a loss of $72,692 for Q3 2025, has an accumulated deficit of $775,569, and negative operating cash flows of $479,644, raising substantial doubt about its ability to continue as a going concern within one year.
• Reliance on Future Financing: The company's ability to continue as a going concern is dependent on improving profitability and continuing financial support from shareholders or external financing, with no assurance that future financing will be available or on satisfactory terms.
• Dilution Risk: If additional equity financing is needed, it may contain undue restrictions on operations or cause substantial dilution for existing stockholders.
• Internal Control Weaknesses: Disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses including: lack of a functioning audit committee, inadequate segregation of duties and effective risk assessment, insufficient written policies and procedures for accounting and financial reporting, and lack of an internal audit function.
• Revenue Concentration: In 2024, 100% of revenue came from two major customers. While 2025 revenue is $0, this highlights potential vulnerability if the company relies on a few clients when revenue resumes.
• Exchange Rate Risk: Fluctuations in the Malaysian Ringgit (RM) to United States Dollar (US$) exchange rate could impact reported income.
• Acquisition Risk: The planned acquisition of Yijun (Shanghai) Biotecholgy Co Ltd. is a significant strategic move, and its successful completion and integration are subject to various risks.

Future Outlook

Management states that the company is moving into long-term strategies on acquisitions, with a significant advance payment made for the planned acquisition of Yijun (Shanghai) Biotecholgy Co Ltd., expected to be completed by Q2 2026. The company expects increased levels of operations going forward to result in more significant cash flow, but its ability to continue as a going concern is dependent on improving profitability and securing future financing.

Management Comments

• The company is moving in to long term strategies on acquisitions.
• We expect increased levels of operations going forward will result in more significant cash flow.
• Management believes the existing shareholders or external financing will provide the additional cash to meet the Company's obligations as they become due.
• No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company.

Industry Context

The company operates in the data analytics and e-commerce grocery market, specifically in Southeast Asia. The complete cessation of revenue from data analytic services in the current period suggests a significant disruption or pivot in its core business model, potentially shifting from direct service provision to an investment holding company focused on acquisitions, as evidenced by the planned biotechnology acquisition. This move into biotechnology, if successful, would represent a diversification away from its stated core business of grocery market data analytics.

Comparison to Industry Standards

• The complete absence of revenue and a significant net loss for the period are highly unusual and unfavorable compared to typical operating companies in the data analytics or e-commerce sectors.
• The identified material weaknesses in internal controls, including the lack of a functioning audit committee and inadequate segregation of duties, fall significantly below standard corporate governance practices for publicly traded companies, especially compared to larger, more established industry players.
• The reliance on equity financing to cover operating losses and fund strategic acquisitions, coupled with a "going concern" warning, indicates a financial position far weaker than industry benchmarks for healthy, growing technology or e-commerce firms.
• The shift in strategic focus towards a biotechnology acquisition, while potentially offering future growth, deviates sharply from the company's stated expertise in grocery market data analytics, making direct industry comparisons challenging without further details on the acquisition target.

Management Changes

Corporate Governance

Legal Proceedings

• No material, active, or pending legal proceedings against the company.
• No proceedings in which any directors or officers are an adverse party or have a material interest adverse to the company.

Related Party Transactions

• Other payables and accruals included $53,929 (as of September 30, 2025) and $26,464 (as of December 31, 2024) to related parties, which are unsecured, interest-free, and repayable on demand.
• Jocom MShopping Sdn. Bhd. (where former CEO/CFO were directors) generated $0 revenue for the company in 2025, down from $6,000 in 2024.
• Director allowances paid to Joshua Sew ($3,531) and Agnes Chua ($699) in 2025 before their resignation.
• Director allowance paid to Loke Weng Chan ($942) in 2025 after his appointment.
• Salary ($16,960) and consulting fee ($72,630) paid to Loke Yu in 2025.
• Accounting fee of $13,599 paid to Khoo Ghi Geok in 2025 (shareholder).

Stakeholder Impact

• Shareholders: Significant dilution from recent share issuances (8,000,000 shares). Equity turned positive, but accumulated losses increased. The "going concern" warning and internal control weaknesses pose substantial risks to investment value.
• Employees: Management changes indicate a restructuring at the top. The shift in strategic focus and operational losses could create uncertainty regarding job security or future growth opportunities within the original business segments.
• Customers: Complete cessation of revenue from data analytic services suggests current customers are no longer being served or the business model has changed, potentially impacting service continuity.
• Creditors: The "going concern" warning and negative operating cash flows increase credit risk. Related party payables are unsecured and interest-free, indicating reliance on internal or closely connected funding.
• Suppliers: No major supplier concentration risk identified, but overall financial health could impact ability to pay suppliers in the future.

Next Steps

• Complete the acquisition of Yijun (Shanghai) Biotecholgy Co Ltd. by Q2 2026.
• Address the material weaknesses in internal controls over financial reporting.
• Improve profitability and secure additional financing to alleviate going concern doubts.

Key Dates

Recommendation

The company exhibits severe financial distress with zero revenue, substantial net losses, and negative operating cash flow, leading to a "going concern" warning. The identified material weaknesses in internal controls indicate significant governance and operational risks. While a capital raise occurred and an acquisition is planned, the current operational performance is unsustainable, and the strategic pivot into biotechnology is unproven and highly speculative given the company's prior focus. These factors collectively point to a high-risk investment with significant downside potential.

Keywords

Data Analytics, SEC Filing, 10-Q, Financial Report, Quarterly Results, Going Concern, Capital Raise, Acquisition Strategy, Software Solution, Corporate Governance, Internal Controls, Malaysia, E-commerce, Biotechnology